Latest Leadership News

Rapid Critical Metals has obtained its initial drilling approval for the Webbs Silver Project, setting the stage for an RC drill program targeting extensions of a newly discovered parallel silver lode and existing ore zones.

GreenTech Metals has raised $7.5 million through an oversubscribed placement to accelerate exploration and development at its Munni Munni and Whundo projects in Western Australia's West Pilbara.

4DS Memory is accelerating commercialisation of its 60nm ReRAM technology in India, aligning with the country’s AUD$25 billion semiconductor investment and targeting mature-node industrial and defence sectors.

EDU Holdings delivered a transformational FY25 with nearly doubled revenue and a debt-free balance sheet, driven by strong growth in its higher education arm Ikon. The company started FY26 on a solid footing despite regulatory headwinds.

Ainsworth Game Technology has confirmed Ryan Comstock as CEO after six months as acting chief, tying his pay to company performance through incentive plans.

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.

Besra Gold appoints Dr Raymond Shaw as CEO, leveraging his four decades of experience to steer the Bau Gold project through ongoing operational and strategic hurdles.

Accordant Group has closed its pro rata renounceable rights offer, securing NZD 5 million and increasing the Hull Family Trust's voting stake to nearly 65%.

Doctor Care Anywhere has snapped up the GLP-1 and medicated weight-loss business of Outcome Diagnostics and MedicSpot for £850,000, adding £5.3 million in trailing revenue and expanding its direct-to-consumer footprint in the UK.

Dyno Nobel’s explosives business drove a 28% EBIT jump in 1H26 as the company completed $558m of its $900m buyback and sealed the sale of its fertilisers unit.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

Inghams Group has unveiled a comprehensive strategy to stabilise operations, optimise assets, and grow value, reaffirming FY26 EBITDA guidance between $180 million and $200 million amid ongoing cost pressures.